HCC1428 BL細胞
器官來源： 外周血
細胞形態： **樣
運輸方式： 凍存運輸
數量： 大量
細胞類型： B**細胞
是否是腫瘤細胞： 0
物種來源： 人
ATCC Number： CRL-2328?
生長狀態： 懸浮生長，多細胞聚集
Designations: HCC1428 BL
Depositors: AF Gazdar, AK Virmani
HCC1428 BL細胞Biosafety Level: 2
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension, multicell aggregates
Organism: Homo sapiens
Morphology: lymphoblast
Source: Organ: peripheral blood
Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. HCC1428 BL細胞Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email [email protected], or Fax: (214) 951-0935.
HCC1428 BL細胞Applications: HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene.
Gender: female
Ethnicity: Caucasian, White
Comments: HCC1428 BL is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from the same patient as the breast carcinoma cell line HCC1428.
HCC1428 was derived from a female who harbored a homozygous deletion in the FHIT gene. The FHIT gene, which spans the FRA3B fragile site at chromosome 3p14.2, is a candidate tumor suppressor gene in breast and other cancers. [32258]
The homozygous deletion in the FHIT gene is retained in the lymphoblastoid line.
There is a familial history of breast cancer (maternal grandmother).
HCC1428, a metastatic breast adenocarcinoma cell line, is available as ATCC CRL-2327.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension in fresh medium at 5 X 10(5) viable cells/ml.
Interval: Maintain cultures at cell concentrations between 5 X 10(5) and 1.5 X 10(6) viable cells/ml.
Medium Renewal: HCC1428 BL細胞Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-2327
References: 32258: Ahmadian M, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res. 57: 3664-3668, 1997. PubMed: 9288768
38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771
